PT - JOURNAL ARTICLE AU - Quinonez, Elena AU - Vahed, Majid AU - Shahraki, Abdolrazagh Hashemi AU - Mirsaeidi, Mehdi TI - A time series forecasting of the proportion of SARS-CoV-2 N501Y lineage in North America AID - 10.1101/2021.03.30.21254648 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.30.21254648 4099 - http://medrxiv.org/content/early/2021/03/31/2021.03.30.21254648.short 4100 - http://medrxiv.org/content/early/2021/03/31/2021.03.30.21254648.full AB - Introduction The outbreak of pneumonia known as SARS-COV-2 and newly-emerging South African (B.1.351), the United Kingdom (B.1.1.7) and Brazil (P.1) variants have led to a more infectious virus and potentially more substantial loss of neutralizing activity by natural infection or vaccine-elicited antibodies.Methods We identified prevalent mutations using the spike receptor-binding domain (S-RBD) of SARS-CoV-2 deposited in the Nextstrain global database and comparing them to the Wuhan-Hu-1/2019 genomic sequence as a reference. Then we calculated the percentages of mutant genomes from the total regional subsample isolates from December 2019 to the end of January 2021. We developed two separate time series forecasting models for the SARS-CoV-2 B.1.1.7 variant. The computational model used the structure of the S-RBD to examine its interactions with the neutralizing antibody, named CV30 (isolated from a patient), and human angiotensin-converting enzyme 2 (hACE-2), based on a hybrid algorithm of template-based modeling to predict the affinity of S protein to the neutralizing antibodies and hACE-2 receptor.Results The proportion of the B.1.1.7 strain in North America is growing fast. From these computations, it seems that the S-RBD and hACE-2 proteins are less favorable for the South African strain (K417N, E484K, and N501Y) as compared to the wild type structure and more favorable for B.1.1.7 and P.1 variants. In the present of crystallized CV30 neutralizing antibodies, docking scores suggest antibodies can be partially neutralize the B.1.1.7 variant, and, less efficiently, the B.1.351 and P.1 variants.Conclusion The rapid evolution of SARS-CoV-2 has the potential to allow the newly-emerged B.1.351, and P.1 variants to escape from natural or vaccine-induced neutralizing immunity and viral spreading.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable. Nextstrain is an all-source code is freely available under the terms of the GNU Affero General Public License. Nextstrain is supported by NIH for research on pathogens including SARS-CoV2. We have accessed to de-identifiable data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated and analyzed during this study are included in this article [and its supplementary information files].SARS-CoV1Severe acute respiratory syndrome coronavirus 1MERS-CoVMiddle East respiratory syndrome coronavirusS-RBDSpike receptor-binding domainhACE-2Human angiotensin-converting enzyme 2U.SUnited StateU.KUnited KingdomCOVID19Coronavirus disease 2019CDCCenters for Disease ControlGISAIDGlobal Initiative on Sharing All Influenza DataCSB PDBProtein Data BankRMSDRoot-mean-square deviation